Caribou Biosciences, Inc. (NASDAQ:CRBU) Short Interest Up 6.8% in July

Caribou Biosciences, Inc. (NASDAQ:CRBU) was the recipient of a large growth in short interest in July. As of July 31st, there was short interest totalling 12,430,000 shares, a growth of 6.8% from the July 15th total of 11,640,000 shares. Based on an average daily trading volume, of 2,480,000 shares, the days-to-cover ratio is presently 5.0 days. Approximately 15.6% of the shares of the stock are sold short.

Wall Street Analyst Weigh In

CRBU has been the subject of several research reports. Royal Bank of Canada reiterated an “outperform” rating and set a $14.00 price objective on shares of Caribou Biosciences in a research note on Wednesday, August 7th. HC Wainwright reiterated a “buy” rating and set a $9.00 price target on shares of Caribou Biosciences in a research report on Wednesday, August 14th. Evercore ISI cut shares of Caribou Biosciences from an “outperform” rating to an “inline” rating and lowered their target price for the stock from $13.00 to $3.00 in a research note on Monday, June 3rd. Finally, Truist Financial reiterated a “buy” rating and issued a $19.00 target price on shares of Caribou Biosciences in a research report on Thursday, May 16th. One analyst has rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $15.00.

Institutional Trading of Caribou Biosciences

Several institutional investors have recently made changes to their positions in the company. AQR Capital Management LLC acquired a new stake in Caribou Biosciences during the second quarter worth $30,000. Point72 DIFC Ltd boosted its position in shares of Caribou Biosciences by 389.4% during the second quarter. Point72 DIFC Ltd now owns 30,157 shares of the company’s stock worth $49,000 after buying an additional 23,995 shares during the period. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Caribou Biosciences in the second quarter valued at $52,000. The Manufacturers Life Insurance Company raised its holdings in shares of Caribou Biosciences by 16.8% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 36,489 shares of the company’s stock valued at $60,000 after buying an additional 5,244 shares during the period. Finally, China Universal Asset Management Co. Ltd. lifted its stake in Caribou Biosciences by 66.5% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 17,024 shares of the company’s stock worth $88,000 after acquiring an additional 6,798 shares in the last quarter. Hedge funds and other institutional investors own 77.51% of the company’s stock.

Caribou Biosciences Trading Up 4.3 %

NASDAQ CRBU traded up $0.09 on Monday, reaching $2.18. 560,624 shares of the company were exchanged, compared to its average volume of 1,945,867. The business’s fifty day moving average price is $1.97 and its 200 day moving average price is $3.85. The stock has a market capitalization of $196.89 million, a P/E ratio of -1.50 and a beta of 2.30. Caribou Biosciences has a fifty-two week low of $1.50 and a fifty-two week high of $8.33.

Caribou Biosciences (NASDAQ:CRBU) last announced its quarterly earnings data on Tuesday, August 6th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.04. Caribou Biosciences had a negative net margin of 345.05% and a negative return on equity of 33.42%. The firm had revenue of $3.46 million during the quarter, compared to analyst estimates of $3.31 million. Equities research analysts forecast that Caribou Biosciences will post -1.8 earnings per share for the current year.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.